Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (558)	6/14/2004 7:27:30 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1336

A little light surfing today: med.nyu.edu "aggresomes" the-scientist.com --this happens to have Kopito in it, followed him over from 'Biosynthesis and Degradation of CFTR' proteasome.com a better copy of the figure for printing proteasome.com oh my god, it is not so complicated, heh This stuff rings a bell, here is something for the Rigelites: srinstitute.com The Discovery and Development of E3 Ligase Inhibitors in Inflammation and Virology -------------------------------------------------------------------------------- Date: Monday, June 21, 2004 Time: 4:15 PM to 4:45 PM Place: Park Hyatt at the Bellevue We have developed high throughput biochemical and cell based screens to examine the activity of the E3 ligase TRAF6, a critical signaling enzyme in the inflammation cascade initiated by Il-1. Various aspects of ligase HTS will be discussed, as well as follow up assays to determine selectivity and specificity in this enzyme class. Multiple functional cell based screens to monitor progress in the chemical SAR of several scaffold series will be presented. Parallel programs examining the role of E3 ligases in regulating HIV pathogenesis will also be presented. Just as kinase “friendly” scaffolds have led to the development of clinical candidates against that class of target, our efforts are focused on discovering and developing E3 ligase “friendly” inhibitors, that can form the foundation for developing a class of small molecule that can be evolved to target several members of this exciting new class of drug targets. Donald Payan, Ph.D. Chief Scientific Officer RIGEL Anyway, back to CF, I sold Rigel when it was 50% lower than where it is now, my bad. Here is the patent which covers using that spice for CF (I hope he has to package his tumeric or whatever it is in little aav capsules, tee hee) United States Patent Application 20030149113 Kind Code A1 Caplan, Michael J. ; et al. August 7, 2003 -------------------------------------------------------------------------------- Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease Abstract This invention provides the methodology and agents for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins. I was looking at the tgen ITR patent, and had to go here for some GT 101: Commentary Size does matter: overcoming the adeno-associated virus packaging limit Terence R Flotte respiratory-research.com This will take you to the Englehardt lab, and possibly right back to reading about the proteasome again. uiowa.edu In a second strategy developed in Engelhardt's lab, and also licensed to Targeted Genetics Corporation, this disadvantageous tagging process can be disrupted, greatly increasing the efficiency by which AAV delivers its genes to the nucleus. However, I did not intend to trip on ubiquitin, I was merely spinning my wheels a bit today and having some fun with google again.